Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: A multicenter observational cohort study (TCTG 2nd-BV study)

Medical Oncology

Volumn 29, Issue 4, 2012, Pages 2842-2848

  Moriwaki, Toshikazu ^a   Bando, Hideaki ^b   Takashima, Atsuo ^c   Yamazaki, Kentaro ^d   Esaki, Taito ^e   Yamashita, Keishi ^f   Fukunaga, Mutsumi ^g   Miyake, Yasuhiro ^h   Katsumata, Kenji ⁱ   Kato, Satoshi ^j   Satoh, Taroh ^k   Ozeki, Mitsuharu ^l   Baba, Eishi ^m   Yoshida, Shigemasa ⁿ   Boku, Narikazu ^o   Hyodo, Ichinosuke ^a  

^a UNIVERSITY OF TSUKUBA HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d SHIZUOKA CANCER CENTER   (Japan)

^e NATIONAL KYUSHU CANCER CENTER   (Japan)

^f SAITAMA MEDICAL UNIVERSITY   (Japan)

^g SAKAI MUNICIPAL HOSPITAL   (Japan)

^h Minoh City Hospital   (Japan)

ⁱ TOKYO MEDICAL UNIVERSITY   (Japan)

^j Iwate Prefectural Central Hospital   (Japan)

^k KINKI UNIVERSITY   (Japan)

^l IBARAKI PREFECTURAL CENTRAL HOSPITAL   (Japan)

^m KYUSHU UNIVERSITY HOSPITAL   (Japan)

ⁿ NATIONAL HOSPITAL ORGANIZATION MITO MEDICAL CENTER   (Japan)

^o ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Bevacizumab; Colorectal cancer; FOLFIRI; FOLFOX; Irinotecan; Second line chemotherapy

Indexed keywords

BEVACIZUMAB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ANOREXIA; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERTENSION; INFECTION; INFUSION RELATED REACTION; INTERSTITIAL PNEUMONIA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NEUROPATHY; NEUTROPENIA; ORAL MUCOSITIS; OVERALL SURVIVAL; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; THROMBOCYTOPENIA; THROMBOEMBOLISM; WOUND HEALING IMPAIRMENT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COHORT STUDIES; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS;

EID: 84867980802     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-0151-2     Document Type: Article

References (17)

1. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22:229-37.
2. Sobrero A, Ackland S, Clarke S, et al. Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. Oncology. 2009;77:113-9.
3. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013-9.
4. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-42.
5. Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study. J Clin Oncol. 2007;25:4779-86.
6. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25:1539-44.
7. ETHICAL guidelines for epidemiological research. http://www.niph.go.jp/ wadai/ekigakurinri/guidelines.pdf.
8. Kuebler JP, Wieand HS, O'Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 2007;25:2198-204.
9. Haller DG, Tabernero J, Maroun J, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011;29:1465-71.
10. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343-51.
11. Peeters M, Price TJ, Cervantes A, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28:4706-13.
12. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359:1757-65.
13. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:1626-34.
14. Yildiz R, Buyukberber S, Uner A, et al. Bevacizumab plus irinotecan-based therapy in metastatic colorectal cancer patients previously treated with oxaliplatin-based regimens. Cancer Invest. 2010;28:33-7.
15. Van Cutsem E, Rivera F, Berry S, et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol. 2009;20:1842-7.
16. Kozloff M, Yood MU, Berlin J, et al. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist. 2009;14:862-70.
17. Bekaii-Saab TS, Bendell JC, Cohn AL, et al. Bevacizumab (BV) plus chemotherapy (CT) in second-line metastatic colorectal cancer (mCRC): Initial results from ARIES, a second BV observational cohort study (OCS). J Clin Oncol 2010;28:15s (suppl; abstr 3495).